Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drop could stop pterygium growth without surgery

NCT ID NCT05456425

Disease control Sponsor: Cloudbreak Therapeutics, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 trial tests CBT-001 eye drops against a placebo in 660 people with pterygium, a non-cancerous growth on the eye's surface. The goal is to see if the drops can reduce redness and stop the growth from getting bigger over 24 months. If successful, it could offer a drug-based alternative to surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CBT-001 eye drop
What this could lead to
If it works, this could provide a non-surgical treatment to control pterygium, reducing redness and preventing the growth from worsening.
What could go wrong
This is a Phase 3 trial, but results are not yet reported. The treatment may not be more effective than placebo, and long-term safety is still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

660 people

The number who actually took part.

Started

Jun 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Pterygium with conjunctival hyperemia Exclusion Criteria: Pterygium removal within the last 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pterygium are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pterygium

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pterygium

Contacts and locations

Locations

  • 1st Affiliated Hospital of University of South China

    Hengyang, 421001, China

  • Advanced Eye Centre PGIMER

    Chandigarh, Chandigarh, 160012, India

  • Advanced Research; LLC

    Deerfield Beach, Florida, 33064, United States

  • Auckland Eye

    Auckland, 1050, New Zealand

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

  • Beijing Tongren Hospital; CMU

    Beijing, 100730, China

  • Bendigo Eye Clinic

    Bendigo, Victoria, 3021, Australia

  • Bruce A. Segal, MD

    Delray Beach, Florida, 33484, United States

  • Center for Sight

    Henderson, Nevada, 89052, United States

  • Clinical Trials of Texas

    San Antonio, Texas, 78229, United States

  • DCT-Shah Research, LLC dba Discovery Clinical Trials

    McAllen, Texas, 78572, United States

  • Emerson Clinical Research Institute, LLC

    Falls Church, Virginia, 22046, United States

  • Eye Hospital of Shandong First Medical University

    Qingdao, 250021, China

  • Eye Hospital of Wenzhou Medical University

    Wenzhou, 325027, China

  • Eye Institute

    Auckland, 1050, New Zealand

  • Eye Research Foundation

    Newport Beach, California, 92663, United States

  • Eyeclinic Albury Wodonga

    Albury, New South Wales, 2640, Australia

  • Global Research Mangement

    Glendale, California, 91204, United States

  • Hainan Provincial Eye Hospital

    Haikou, 570311, China

  • Horizon Eye Specialists & LASIK Center

    Sun City, Arizona, 83531, United States

  • Icare Eye Hospital

    Noida, Uttar Pradesh, 201301, India

  • Inland Eye Specialists

    Hemet, California, 92545, United States

  • International Research Center

    Tampa, Florida, 33603, United States

  • L V Prasad Eye Institute

    Bhubaneswar, Odisha, 751024, India

  • Narayana Nethralaya

    Bangalore, Karnataka, 560010, India

  • Netralaya Super Specialty Eye Hospital

    Ahmedabad, Gujarat, 380006, India

  • North Bay Eye Associates INC

    Petaluma, California, 94954, United States

  • R and R Eye Research

    San Antonio, Texas, 78229, United States

  • SP Medical College and AG of Hospitals

    Bikaner, Rajasthan, 334001, India

  • Santa Barbara Eye Care

    Santa Barbara, California, 93105, United States

  • Shultz Chang Vision

    Northridge, California, 91325, United States

  • Southern Eye Specialists

    Christchurch, 8013, New Zealand

  • Sunshine Eye Surgeons

    St Albans, Victoria, 3021, Australia

  • Sydney Eye Hospital

    Sydney, New South Wales, 2000, Australia

  • The Centre for Eye Research Australia

    East Melbourne, Melbourne, 3002, Australia

  • The Eye Care Institute

    Louisville, Kentucky, 40206, United States

  • The First Affiliated Hospital of NC University

    Nanchang, 330006, China

  • The Second People's Hospital of Yunnan Province

    Kunming, 650021, China

  • Trinity Research Group

    Dothan, Alabama, 36301, United States

  • Union Hospital Tongji Medical College

    Wuhan, 430022, China

  • Vance Thompson Vision

    Sioux Falls, South Dakota, 57108, United States

  • West China Hospital of Sichuan University

    Chengdu, 610041, China

  • West Coast Eye Institute

    Bakersfield, California, 93311, United States

  • Xiamen Eye Center of Xiamen University

    Xiamen, 361004, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.